<DOC>
	<DOCNO>NCT00254319</DOCNO>
	<brief_summary>Avastin novel antiangiogenic agent recently show improve response rate survival patient advance nonsquamous non-small cell lung cancer add front-line carboplatin/paclitaxel chemotherapy , routinely incorporated treatment patient . Alimta recently approve chemotherapeutic show activity non-small cell lung cancer give alone combination carboplatin , favorable toxicity profile andrequires brief ( 10 minute ) infusion time . Therefore propose study combination Avasin , Alimta , Carboplatin administer front-line therapy patient advance nonsquamous non-small cell lung cancer .</brief_summary>
	<brief_title>Previously Untreated Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>I 18 year age old . I advance nonsmall lung cancer . I major surgical procedure within 28 day prior start treatment . I high blood pressure control . I heparin , coumadin lovonox treatment medical condition . I serious wound heal problem . I receive previous treatment , except radiation therapy disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>